Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6

Sean Ekins, Mark Vandenbranden, Barbara J. Ring, Jennifer S. Gillespie, Tian J. Yang, Harry V. Gelboin and Steven A. Wrighton
Journal of Pharmacology and Experimental Therapeutics September 1998, 286 (3) 1253-1259;
Sean Ekins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Vandenbranden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara J. Ring
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer S. Gillespie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tian J. Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry V. Gelboin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Wrighton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Previous studies in this laboratory have determined the lack of specificity of several antibody and substrate probes of CYP2B6. The goals of the current study were to examine the expression of CYP2B6 in a bank of human liver microsome (HLM) samples using a new specific monoclonal antibody (MAb 49-10-20) and to further characterize the substrate specificity of CYP2B6. A 100-fold variability in expression of immunodetectable CYP2B6 was demonstrated in a bank of 19 HLM samples (0.7 pmol/mg protein to 71.1 pmol/mg protein) using MAb 49-10-20. CYP2B6 levels were found to significantly (P < .0001) correlate with S-mephenytoin N-demethylation to nirvanol (r2 = 0.89), 7-hydroxy-4-trifluoromethylcoumarin formation (r2 = 0.81) and several markers of CYP3A levels and activity. The relationships between nirvanol formation and CYP3A levels or activity were found to depend on two HLM samples. Km (apparent) values were generated for benzyloxyresorufin O-deethylation (1.3 μM), benzphetamineN-demethylation (93.4 μM), 3-cyano 7-ethoxycoumarinO-deethylation (71.3 μM), midazolam 1′-hydroxylation (46.1 μM) and 4-chloromethyl-7-ethoxycoumarin O-deethylation (33.7 μM) using expressed CYP2B6. Testosterone 16β-hydroxylation by expressed CYP2B6 resulted in atypical kinetics characteristic of substrate activation. The data best fit the Hill equation with aKm (apparent) of 50.5 μM and an nof 1.3 (n = number of sites bound by activator). In conclusion, the highly specific MAb 49-10-20 was used to provide further confirmation that S-mephenytoinN-demethylation to nirvanol is a CYP2B6 selective probe. Finally, some, but not all substrates of CYP2B6 demonstrate autoactivation.

Footnotes

  • Send reprint requests to: Dr. Steven Wrighton, Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Drop Code 0825, Indianapolis, IN 46285.

  • ↵1 Current address: Central Research Division, Pfizer Inc., Groton, CT 06340.

  • Abbreviations:
    4Cl-7-EC
    4-chloromethyl-7-ethoxycoumarin
    4Cl-7-HC
    4-chloromethyl-7-hydroxycoumarin
    3CN-7-EC
    3-cyano-7-ethoxycoumarin
    3CN-7-HC
    3-cyano-7-hydroxycoumarin
    CYP
    cytochrome P450
    7-EFC
    7-ethoxy-4-trifluoromethylcoumarin
    7-HFC
    7-hydroxy-4-trifluoromethylcoumarin
    HPLC
    high-performance liquid chromatography
    TBA
    tetrabutylammonium phosphate
    MAb
    monoclonal antibody
    • Received March 26, 1998.
    • Accepted May 10, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 286, Issue 3
1 Sep 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6

Sean Ekins, Mark Vandenbranden, Barbara J. Ring, Jennifer S. Gillespie, Tian J. Yang, Harry V. Gelboin and Steven A. Wrighton
Journal of Pharmacology and Experimental Therapeutics September 1, 1998, 286 (3) 1253-1259;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6

Sean Ekins, Mark Vandenbranden, Barbara J. Ring, Jennifer S. Gillespie, Tian J. Yang, Harry V. Gelboin and Steven A. Wrighton
Journal of Pharmacology and Experimental Therapeutics September 1, 1998, 286 (3) 1253-1259;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Evidence That Melanocortin 4 Receptor Mediates Hemorrhagic Shock Reversal Caused by Melanocortin Peptides
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics